News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors

May 20, 2023
Ben Kong, PharmD, BCPS
OncologyONCOLOGY Vol 37, Issue 5
Volume 37
Issue 5
Pages: 216-217

Ben Kong, PharmD, BCPS, shares a perspective on a study of biomarkers published recently in ONCOLOGY.

A function of immune checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, is to allow normal tissues to coexist with the immune system and avoid triggering a destructive response. When PD-1 (found on T cells) is bound to PD-L1 (found on normal tissue), it dampens T-cell activation.1 It is now recognized that tumors can also express PD-L1, gaining the ability to escape detection and be allowed to proliferate. Thus, the role of PD-L1 as a biomarker has emerged, and there is interest in the therapeutic opportunity to block the PD-1/PD-L1 interaction.

In 2014, pembrolizumab (Keytruda) was the first PD-1 inhibitor to receive FDA approval for use in melanoma. This was further expanded in 2017 and 2020 to tumors with microsatellite instability–high status and tumor mutational burden (TMB) greater than 10 mut/Mb, respectively. Since then, other PD-1/PD-L1 inhibitors have been approved in various diseases, such as nivolumab (Opdivo), atezolizumab (Tecentriq), avelumab (Bavencio), and durvalumab (Imfinzi). When a response is seen, it tends to be durable and prolonged. Regarding immune-related adverse effects, they can affect any organ system and lead to reactions such as rash, diarrhea, endocrinopathies, musculoskeletal pain, pneumonitis, and more.

The authors of “Biomarkers for Response to Anti–PD-1/ PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis” performed a comprehensive review of 100 studies, encompassing approximately 18,000 patients to address the role of 9 predictive biomarkers across tumor types. With a large data set available to conduct robust statistical analysis, their findings suggest that TMB, PD-L1 immunohistochemistry (IHC), and multiplex IHC/immunofluorescence were sensitive in predicting response across all tumor types, although the authors acknowledge heterogeneity in study design and limited study size. Some of the complexities and nuances may pertain to the assay and clinical interpretation of immune therapies.

Among the antibodies available to assess PD-L1 expression, 4 are associated with the clinical indication (eg, 22C3/pembrolizumab, 28-8/nivolumab, SP263/durvalumab, and SP142/atezolizumab). When interpreting PD-L1 IHC, a number of additional factors need consideration besides the PD-L1 clone, such as the control, tissue fixation, adequate number of tumor cells, and PD-L1 scoring method (tumor proportion score, combined positive score, tumor cell/ immune cell).2,3

The TMB captures somatic alterations within a genomic sequence, and higher values are associated with response to immune therapy. Although the standard method to determine TMB is generally derived from whole exome or genome sequencing, it is not routinely performed due to cost and turnaround. Instead, targeted panels are widely adopted and used to identify oncogenic mutations and estimate TMB. Because of the potential discrepancy, a study explored the performance of panel-based assay compared with whole exome sequencing and observed that variabilities exist among the 11 participating laboratories, leading to either underestimation or overestimation of TMB—likely due to differences in panel size and bioinformatic algorithms.4

The RECIST Working Group has provided guidance in defining and measuring responses to cancer therapies. Unlike traditional therapies, immune modulators tend to have a different pattern of response, which led to the development of iRECIST.5 Specifically, immune modulators can elicit either a delayed clinical response or pseudoprogression—the latter being a phenomenon in which the initial imaging assessment may show new lesions or existing tumors that appear larger, followed by a delayed clinical response. The distinction between pseudoprogression and true progression remains a challenge, so it is currently recommended to continue treatment until the next imaging assessment.

Moving forward, a future toward standardization of analytical methods and interpretation would assist in reducing certain aspects of heterogeneity that are naturally inherent in studies. Doing so would pave the way to better understanding the predictive potential of biomarkers and identifying the patient who may benefit the most from treatment.

DISCLOSURES: Kong is a consultant for Clarified Precision Medicine.

AFFILIATIONS: Oregon Health & Science University and Oregon Health & Science University Knight Cancer Institute

CORRESPONDING AUTHOR(S):

Ben Kong, PharmD, BCPS
Clinical Pharmacy Specialist
Oregon Health & Science University
Email: kong@ohsu.edu
ORCID: 0000-0002-9019-6961

References

  1. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239-245. doi:10.1038/ni1443
  2. Chebib I, Mino-Kenudson M. PD-L1 immunohistochemistry: clones, cutoffs, and controversies. APMIS. 2022;130(6):295-313. doi:10.1111/apm.13223
  3. Prince EA, Sanzari JK, Pandya D, Huron D, Edwards R. Analytical concordance of PD-L1 assays utilizing antibodies from FDA-approved diagnostics in advanced cancers: a systematic literature review. JCO Precis Oncol. 2021;5:953-973. doi:10.1200/PO.20.00412
  4. Merino DM, McShane LM, Fabrizio D, et al; TMB Harmonization Consortium. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer. 2020;8(1):e000147. doi:10.1136/jitc-2019-000147
  5. Seymour L, Bogaerts J, Perrone A, et al; RECIST Working Group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143-e152. doi:10.1016/S1470-2045(17)30074-8. Published correction appears in Lancet Oncol. May 20, 2019
Download Issue PDFDownload PDF
Articles in this issue

The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors
The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors
Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis
Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis
An Arthroscopic Approach for the Intralesional Curettage of Giant Cell Tumor of the Distal Femur: A Case Report
An Arthroscopic Approach for the Intralesional Curettage of Giant Cell Tumor of the Distal Femur: A Case Report
The Painful Problem of Biosimilars in the Clinic
The Painful Problem of Biosimilars in the Clinic
Multidisciplinary Care Is Imperative to the Future of Breast Cancer Treatment
Multidisciplinary Care Is Imperative to the Future of Breast Cancer Treatment
Related Videos
Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.
Shubham Pant, MD, highlights the importance of tailoring treatment in patients with pancreatic cancer by exploring biomarkers.
next-generation sequencing
genomic profiling
cancer cell
Related Content

Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis

May 17th 2023

Oncology Peer Review On-The-Go: 1-on-1 With Richard L. Schilsky, MD, on Molecular Profiling in GI Cancers

March 2nd 2021

Momelotinib Use in the MOMENTUM Trial

May 15th 2023

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019

Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

May 13th 2023

Recap: Experts Discuss the Identification and Appropriate Treatment of GVHD

May 12th 2023

Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis

May 17th 2023

Oncology Peer Review On-The-Go: 1-on-1 With Richard L. Schilsky, MD, on Molecular Profiling in GI Cancers

March 2nd 2021

Momelotinib Use in the MOMENTUM Trial

May 15th 2023

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019

Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

May 13th 2023

Recap: Experts Discuss the Identification and Appropriate Treatment of GVHD

May 12th 2023

Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis

May 17th 2023

Oncology Peer Review On-The-Go: 1-on-1 With Richard L. Schilsky, MD, on Molecular Profiling in GI Cancers

March 2nd 2021

Momelotinib Use in the MOMENTUM Trial

May 15th 2023

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019

Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

May 13th 2023

Recap: Experts Discuss the Identification and Appropriate Treatment of GVHD

May 12th 2023
Related Content

Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis

Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis

May 17th 2023
Article

Arshiya Mariam, BS, and colleagues report the findings of a large meta-analysis assessing the ability of various biomarkers to predict responses to immune checkpoint inhibition.


Oncology Peer Review On-The-Go: 1-on-1 With Richard L. Schilsky, MD, on Molecular Profiling in GI Cancers

Oncology Peer Review On-The-Go: 1-on-1 With Richard L. Schilsky, MD, on Molecular Profiling in GI Cancers

March 2nd 2021
Podcast

Schilsky joined CancerNetwork®’s podcast to discuss ASCO’s Advance of the Year, the top priorities moving forward, and the COVID-19 pandemic.


Momelotinib Use in the MOMENTUM Trial

Momelotinib Use in the MOMENTUM Trial

May 15th 2023
Article

Lead study author Rubin Mesa, MD, discusses findings from the MOMENTUM trial assessing the use of momelotinib in the treatment of myelofibrosis.


Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

Recap: CLEAR Trial Regimen as a Standard for Frontline Clear Cell RCC: Impressive Efficacy but Personalization Is Needed

May 13th 2023
Article

A panel of experts discuss the updated results of the phase 3 CLEAR trial presented at the 2022 International Kidney Cancer Symposium.


Recap: Experts Discuss the Identification and Appropriate Treatment of GVHD

Recap: Experts Discuss the Identification and Appropriate Treatment of GVHD

May 12th 2023
Article

Preet M. Chaudhary, MD, and his medical team discuss graft-vs-host disease (GVHD) and their treatment experiences alongside a patient, Hector Cuevas.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.